Clinical Report: Radiotherapy in Advanced Metastatic Bladder Cancer
Overview
Radiotherapy plays a crucial role in symptom palliation and disease control in metastatic bladder cancer (MetBC). Hypofractionated radiotherapy schedules provide effective relief of urinary symptoms, while stereotactic ablative radiotherapy (SABR) shows promise in targeting oligometastatic disease to potentially improve outcomes.
Background
Bladder cancer causes significant mortality worldwide, with 10–15% of patients presenting with metastatic disease at diagnosis. Metastatic bladder cancer has a poor prognosis, with less than 10% five-year survival. First-line treatment typically involves platinum-based chemotherapy, with maintenance immunotherapy improving survival in responsive cases. Radiotherapy is established for localized muscle-invasive bladder cancer and is increasingly used for palliation and targeted treatment of metastases in advanced disease.
Data Highlights
Study
Radiotherapy Schedule
Symptom Relief
Local Disease Control
Toxicity
Early studies [17]
Hypofractionated
Almost universal haematuria relief; >50% complete control
Not specified
Not specified
MRC-BA09 trial [14]
3 fractions
Effective palliation
Not specified
Not specified
36 Gy in 6 weekly fractions [19]
36 Gy/6 fractions
92% disease control at 3 months
7% local progression at 1 year; 17% at 2 years
Grade 3 urinary toxicity 18%; GI toxicity 4% during treatment; 6.5% grade 3 toxicity at 6 months
Haematuria relief 54%; dysuria/frequency 57%; pain control 48%
Not specified
Not specified
BED ≥36 Gy vs <36 Gy [22,23]
BED ≥36 Gy
Haematuria response 77% vs 61%; longer control (8.4 vs 0.7 months)
No OS difference
Not specified
Key Findings
Hypofractionated radiotherapy provides effective palliation of haematuria and urinary symptoms in metastatic bladder cancer.
The 36 Gy in six weekly fractions schedule achieves durable symptom control and local disease control with manageable toxicity.
Higher biologically effective doses (BED ≥36 Gy) correlate with better haematuria control and longer symptom relief but do not improve overall survival.
Patient selection based on performance status, disease burden, and prognosis is critical to optimize palliative radiotherapy benefits.
SABR is emerging as a promising approach for treating oligometastatic bladder cancer to potentially prolong disease control.
About 25% of patients receiving palliative radiotherapy discontinue treatment or die within one month, highlighting the need for careful clinical judgment.
Clinical Implications
Radiotherapy should be considered a key modality for symptom palliation in metastatic bladder cancer, especially for controlling haematuria and pelvic pain. Hypofractionated schedules such as 36 Gy in six fractions offer a balance of efficacy and tolerability. SABR may provide additional benefit in selected patients with limited metastatic burden. Careful patient selection is essential to maximize benefit and minimize treatment burden.
Conclusion
Radiotherapy remains an effective and accessible option for symptom management in metastatic bladder cancer, with emerging evidence supporting its role in oligometastatic disease control. Optimizing treatment schedules and patient selection can enhance clinical outcomes and quality of life.
References
Global bladder cancer mortality and metastatic presentation data [1,2]
UK bladder cancer mortality and socioeconomic impact [3,4]
Prognosis and chemotherapy outcomes in metastatic bladder cancer [5,6]
Maintenance immunotherapy with avelumab [7]
Radiotherapy in muscle-invasive bladder cancer and palliation [3,10-14]
MRC-BA09 and other palliative radiotherapy trials [14,17-23]
